Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.53 |
| ▸ | STS | P08842 | 14/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551113 | 0.93 | MIF (0.58) | MIFSTSHDAC3HDAC1HDAC2 | |
| SCHEMBL3545608 | 0.93 | MIF (0.46) | MIFSTSCA2CA7CA9 | |
| SCHEMBL3543201 | 0.88 | MIF (0.50) | MIFSTSCA2CA7NPC1 | |
| SCHEMBL2766273 | 0.88 | STS (0.43) | MIFSTSCA2CA7CA9 | |
| SCHEMBL13166570 | 0.87 | MIF (0.44) | MIFSTSCA2CA7CA9 | |
| SCHEMBL3548006 | 0.86 | MIF (0.50) | MIFSTSCA2CA7NPC1 | |
| SCHEMBL3546808 | 0.86 | CA2 (0.45) | MIFSTSCA2CA7CA9 | |
| SCHEMBL3547917 | 0.83 | MIF (0.67) | MIFHDAC3HDAC1HDAC2CA2 | |
| SCHEMBL3543484 | 0.83 | STS (0.40) | MIFSTSCA2CA7CA9 | |
| SCHEMBL2766527 | 0.82 | MIF (0.54) | MIFHDAC3HDAC1HDAC2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | MIF 2538/4885STS 1186/4885HDAC3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.